ACE Phenotyping as a Guide Toward Personalized Therapy with ACE Inhibitors

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 22, Issue 4, 2017, Pages 374-386

  Danilov, Sergei M ^a   Tovsky, Stan I ^a   Schwartz, David E ^a   Dull, Randal O ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

ACE conformation; ACE inhibitor; ACE phenotyping; angiotensin converting enzyme; blood pressure; hypertension; nonresponders

Indexed keywords

CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; HYDROCHLOROTHIAZIDE; PLACEBO; ACE PROTEIN, HUMAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TETRAZOLE DERIVATIVE; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME SUBSTRATE; FEMALE; HUMAN; HYPERTENSION; LONG TERM CARE; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG MONITORING; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; GENOTYPE; METABOLISM; PATHOPHYSIOLOGY; PATIENT SELECTION; PHARMACOGENETIC TESTING; PHARMACOGENETIC VARIANT; PHARMACOGENETICS; PREDICTIVE VALUE; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG MONITORING; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ENALAPRIL; GENOTYPE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; PATIENT SELECTION; PEPTIDYL-DIPEPTIDASE A; PHARMACOGENETICS; PHARMACOGENOMIC TESTING; PHARMACOGENOMIC VARIANTS; PHENOTYPE; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; SODIUM CHLORIDE SYMPORTER INHIBITORS; TETRAZOLES; TREATMENT OUTCOME;

EID: 85020429058     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248416686188     Document Type: Article

References (70)

1. Menard J, Patchett AA,. Angiotensin-converting enzyme inhibitors. Adv Protein Chem. 2001; 56: 13-75.
2. Pfeffer MA, Frohlich ED,. Improvements in clinical outcomes with the use of angiotensin-converting enzyme inhibitors: cross-fertilization between clinical and basic investigation. Am J Physiol Heart Circ Physiol. 2006; 291 (5): H2021-H2025.
3. Dzau VJ,. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation. 1988; 77 (6 pt 2): 14-13.
4. Campbell DJ, Kladis A, Dunkan AM,. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension. 1994; 23 (4): 439-449.
5. van Kats JP, Duncker DJ, Haitsma DB, et al. Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II. Circulation. 2000; 102 (13): 1556-1563.
6. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ,. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998; 339 (18): 1285-1292.
7. Azizi M, Junot C, Ezan E, Hallouin MC, Guyene T, Ménard J,. Functional consequences of angiotensin-converting enzyme gene polymorphism on N-acetyl-Ser-Asp-Lys-Pro degradation and angiotensin II production. J Mol Med. 2002; 80 (8): 492-498.
8. Peng H, Carretero OA, Vuljaj N, et al. Angiotensin-converting enzyme inhibitors: a new mechanism of action. Circulation. 2005; 112 (16): 2436-2445.
9. Ferrario CM,. New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism. Hypertension. 2010; 55 (2): 445-452.
10. Attwood S, Bird R, Burch K, et al. Within-patient correlation between antihypertensive effects of atenolol, lisinopril and nifedipine. J Hypertens. 1994; 12 (9): 1053-1060.
11. Menard J, Chatellier G, Day M, Vaur L,. Self-measurement of blood pressure at home to evaluate drug effects by the trough:peak ratio. J Hypertens Suppl. 1994; 12 (8): S21-S25.
12. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ,. Optimisation of antihyper-tensive treatment by crossover rotation of four major classes. Lancet. 1999; 353 (9169): 2008-2013.
13. Sever PS, Chang CL,. Discordant responses to two classes of drugs acting on renin-angiotensin system. J Renin Angiotensin Aldosterone System. 2001; 2 (1): 25-30.
14. Stergiou GS, Roussias LG, Mountokalakis TD,. Intraindividual blood pressure responses to angiotensin-converting enzyme inhibition and angiotensin receptor blockade. J Clin Hypertens. 2005; 7 (1): 18-23.
15. Turner ST, Schwartz GL, Chapman AB, et al. Antihypertensive pharmacogenetics: getting the right drug into the right patient. J Hypertens. 2001; 19 (1): 1-11.
16. Mellen PB, Herrington DM,. Pharmacogenomics of blood pressure response to antihypertensive treatment. J Hypertens 2005; 23 (7): 1311-1325.
17. Rigat B, Humert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F,. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990; 86 (4): 1343-1346.
18. Danser AH, Batenburg WW, van den Meiraker AH, Danilov SM,. ACE phenotyping as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibition. Pharmacol Ther. 2007; 113 (3): 607-618.
19. Ueda S, Meredith PA, Morton JJ, Connell JM, Elliott HL,. ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. Circulation. 1998; 98 (20): 2148-2153.
20. Scharplatz M, Puhan MA, Steurer J, Perna A, Bachmann LM,. Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy?-A systematic review. Curr Control Trials Cardiovasc Med. 2005; 6: 16.
21. Mattace-Raso FU, Sie MP, van der Cammen TJ, et al. Insertion/deletion gene polymorphism of the angiotensin-converting enzyme and blood pressure changes in older adults. The Rotterdam study. J Hum Hypertens. 2007; 21 (9): 736-740.
22. Bhatnagar V, O'Connor DT, Schork NJ, et al. Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. J Hypertens. 2007; 25 (10): 2082-2092.
23. Harrap SB, Tzourio C, Cambien F, et al.PROGRESS Collaborative Group. The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension. 2003; 42 (3): 297-303.
24. Brugts JJ, Isaacs A, de Maat MP, et al. A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. J Hypertens. 2011; 29 (3): 509-519.
25. Tiret L, Rigat B, Visvikis S, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet. 1992; 51 (1): 197-205.
26. Danilov SM, Savoie F, Lenoir B, et al. Development of enzyme-linked immunoassays for human angiotensin I converting enzyme suitable for large-scale studies. J Hypertens. 1996; 14 (6): 719-727.
27. Rossi GP, Narkiewicz K, Cesari M, et al. Genetic determinants of plasma ACE and renin activity in young normotensive twins. J Hypertens. 1999; 17 (5): 647-655.
28. Rice GI, Jones AL, Grant PJ, Carter AM, Turner AJ, Hooper NM,. Circulating activities of angiotensin-converting enzyme, its homologue, angiotensin-converting enzyme 2, and neprilizin in a family study. Hypertension. 2006; 48 (5): 914-920.
29. Montgomery H, Humphries S, Danilov SM,. Is genotype or phenotype the better tool for investigating the role of ACE in human cardiovascular disease? Eur Heart J. 2002; 23 (14): 1083-1086.
30. Danilov S, Jaspard E, Churakova T, et al. Structure-function analysis of angiotensin I-converting enzyme using monoclonal antibodies. J Biol Chem. 1994; 269 (43): 26806-26814.
31. Gordon K, Balyasnikova IV, Nesterovitch AB, Schwartz DE, Sturrock ED, Danilov SM,. Fine epitope mapping of monoclonal antibodies 9B9 and 3G8, to the N domain of human angiotensin I-converting enzyme (ACE) defines a region involved in regulating ACE dimerization and shedding. Tissue Antigens 2009; 75 (2): 136-150.
32. Balyasnikova IV, Skirgello OE, Binevski PV, et al. Monoclonal antibodies 1G12 and 6A12 to the N domain of human angiotensin-converting enzyme: fine epitope mapping and antibody-based method for revelation and quantification of ACE inhibitors in the human blood. J Proteome Res. 2007; 6 (4): 1580-1594.
33. Schilders JE, Wu H, Boomsma F, van den Meiracker AH, Danser AH,. Renin-angiotensin system phenotyping as a guidance toward personalized medicine for ACE inhibitors: can the response to ACE inhibition be predicted on the basis of plasma renin or ACE? Cardiovasc Drugs Ther. 2014; 28 (4): 335-345.
34. Friedland J, Silverstein E,. A sensitive fluorometric assay for serum angiotensin-converting enzyme. Am J Clin Pathol. 1976; 66 (2): 416-424.
35. Piquilloud Y, Reinharz A, Roth M,. Studies on the angiotensin-converting enzyme with different substrates. Biochim Biophys Acta. 1970; 206 (1): 136-142.
36. Danilov SM, Balyasnikova IV, Albrecht RFII, Kost OA,. Simultaneous determination of ACE activity with two substrates provide an information on the nativity of somatic ACE and allow to detect ACE inhibitors in the human blood. J Cardiovasc Pharmacol. 2008; 52 (1): 90-103.
37. Wei L, Alhenc-Gelas F, Corvol P, Clauser E,. The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J Biol Chem. 1991; 266 (14): 9002-9008.
38. Jaspard E, Wei L, Alhenc-Gelas F,. Differences in properties and enzymatic specificities between the two active sites of human angiotensin I-converting enzyme: studies with bradykinin and other natural peptides. J Biol Chem. 1993; 268 (13): 9496-9503.
39. Georgiadis D, Beau F, Czarny B, Cotton J, Yiotakis A, Dive V,. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors. Circ Res. 2003; 93 (2): 148-154.
40. Skirgello OE, Binevski PV, Pozdnev VF, Kost OA,. Kinetic probes for inter-domain cooperation in human somatic angiotensin-converting enzyme. Biochem J. 2005; 391 (pt 3): 641-647.
41. Williams TA, Danilov SM, Alhenc Gelas F, Soubrier F,. A study of chimeras constructed with the two domains of angiotensin I converting enzyme. Biochem Pharmacol. 1996; 51 (1): 11-14.
42. Gu Q, Chen X, Zhong D, Wang Y,. Simultaneous determination of enalapril and enalaprilat in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B. 2004; 813 (1-2): 337-342.
43. Alhenc-Gelas F, Richard J, Courbon D, Warnet JM, Corvol P,. Distribution of plasma angiotensin I-converting enzyme levels in healthy men: relationship to environmental and hormonal parameters. J Lab Clin Med. 1991; 117 (1): 33-39.
44. Boomsma F, de Bruyn JH, Derkx FH, Schalekamp MA,. Opposite effects of captopril on angiotensin I-converting enzyme 'activity' and 'concentration' relation between enzyme inhibition and long-term blood pressure response. Clin Sci. (Lond) 1981; 60 (5): 491-498.
45. Fyhrquist F, Gronhangen-Riska C, Hortling L, Forslund T, Tikkanen I,. Regulation of angiotensin-converting enzyme. J Hypertens. 1983; 1 (suppl 1): 25-30.
46. King SJ, Oparil S,. Converting-enzyme inhibitors increase converting-enzyme mRNA and activity in endothelial cells. Am J Physiol. 1992; 263 (4 pt 1): C743-C749.
47. Chai SY, Perich R, Jackson B, Mendelsohn FA, Johnston CI,. Acute and chronic effects of angiotensin-converting enzyme inhibitors on tissue angiotensin-converting enzyme. Clin Exp Pharmacol Physiol. 1992; 19: 7-12.
48. Costerousse O, Allegrini J., Huang H, Bounhik J, Alhenc-Gelas F,. Regulation of ACE gene expression and plasma levels during rat postnatal development. Am J Physiol. 1994; 267 (5 pt 1): E745-E753.
49. Costerousse O, Allegrini J, Clozel JP, Menard J, Alhenc-Gelas F,. Angiotensin I-converting enzyme inhibition but not angiotensin II suppression alters angiotensin I-converting enzyme gene expression in vessels and epithelia. J Pharmacol Exp Ther. 1998; 284 (3): 1180-1187.
50. Kohlstedt K, Gershome C, Friedrich M, et al. Angiotensin converting enzyme (ACE) dimerization is the initial step in the ACE inhibitor-induced ACE signaling cascade in endothelial cells. Mol Pharmacol. 2006; 69 (5): 1725-1732.
51. Kost OA, Balyasnikova IV, Chemodanova EE, Nikolskaya II, Albrecht RF 2nd, Danilov SM,. Epitope-dependent blocking of the angiotensin-converting enzyme dimerization by monoclonal antibodies to N-terminal domain of ACE: possible link of ACE dimerization and shedding from the cell surface. Biochemistry. 2003; 42 (23): 6965-6976.
52. Danilov SM, Lünsdorf H, Akinbi H, et al. Lysozyme and bilirubin bind to ACE and regulate its conformation and shedding. Sci Rep. 2016; 6: 34913. doi:10.1038/scirep34913.
53. Danilov SM, Balyasnikova IB, Danilova AS, et al. Conformational fingerprinting of the angiotensin-converting enzyme (ACE): 1.Application in sarcoidosis. J Proteome Res. 2010; 9 (11): 5782-5793.
54. Danilov SM, Deinum J, Balyasnikova IV, et al. Detection of mutated angiotensin I-converting enzyme by serum/plasma analysis using a pair of monoclonal antibodies. Clin Chem. 2005; 51 (6): 1040-1043.
55. Nesterovitch AB, Hogarth K, Adarichev VA, et al. Angiotensin I-converting enzyme mutation (Trp1197Stop) causes a dramatic increase in blood ACE. PLoS One. 2009; 4 (12): e8282.
56. Danilov SM, Kalinin S, Chen Z, et al. Angiotensin I-converting enzyme Gln1069Arg mutation impairs trafficking to the cell surface resulting in selective denaturation of the C-domain. PLoS One. 2010; 5 (5): e10438.
57. Danilov SM, Gordon K, Nesterovitch AB, et al. An angiotensin I-converting enzyme mutation (Y465D) causes a dramatic increase in blood ACE via accelerated ACE shedding. PLoS One. 2011; 6 (10): e25952.
58. Persu A, Lambert M, Deinum J, et al. A novel splice-site mutation in angiotensin I-converting enzyme (ACE) gene, c.3691+1G>A (IVS25+1G>A), causes a dramatic increase in circulating ACE through deletion of the transmembrane anchor. PLoS One. 2013; 8 (4): e59537.
59. Danilov SM, Wade MS, Schwager SL, et al. A novel angiotensin I-converting enzyme mutation (S333W) impairs N-domain enzymatic cleavage of the anti-fibrotic peptide, AcSDKP. PLoS One. 2014; 9 (2): e88001.
60. Toutain PL, Lefebvre HP,. Pharmacokinetics and pharmacokinetic/ pharmacodynamics relationships for angiotensin-converting enzyme inhibitors. J Vet Pharmacol Therap. 2004; 27 (6): 515-525.
61. Struthers AD, Anderson G, MacFayen RJ, Fraser C, MacDonald TM,. Non-adherence with ACE inhibitor treatment is common in heart failure and can be detected by routine serum ACE activity assays. Heart. 1999; 82 (5): 584-588.
62. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F,. Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J. 1993; 290 (pt 1): 33-40.
63. Danser AHJ, Schalekamp MA, Bax WA, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation. 1995; 92 (6): 1387-1388.
64. Stergiou GS, Efstathiou SP, Skeva II, Baibas NM, Roussias LG, Mountokalakis TD,. Comparison of the smoothness index, the trough:peak ratio and the morning: evening ratio in assessing the features of the antihypertensive drug effect. J Hypertens. 2003; 21 (5): 913-920.
65. Turner ST, Boerwinkle E, O'Connell JR, et al. Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide. Hypertension. 2013; 62 (2): 391-397.
66. Jacobsen P, Rossing K, Rossing P, et al. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int. 1998; 53 (4): 1002-1006.
67. Jastrzebska M, Widecka K, Naruszewicz M, et al. Effects of perindopril treatment on hemostatic function in patients with essential hypertension in relation to angiotensin converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms. Nutr Metab Cardiovasc Dis. 2004; 14 (5): 259-269.
68. Bénéteau-Burnat B, Baudin B,. Angiotensin-converting enzyme: clinical applications and laboratory investigations on serum and other biological fluids. Crit Rev Clin Lab Sci. 1991; 28 (5-6): 337-356.
69. Kramers C, Danilov SM, Deinum J, et al. Point mutation in the stalk of angiotensin-converting enzyme causes a dramatic increase in serum angiotensin-converting enzyme but no cardiovascular disease. Circulation. 2001; 104 (11): 1236-1240.
70. Petrov MN, Shilo VY, Tarasov AV, et al. Conformational changes of blood ACE in uremia. PLoS One. 2012; 7 (11): e49290.